A new era for patients with Medium Vessel Occlusion 

Late-breaking results show TIGERTRIEVER™ 13 significantly improved blood flow to the brain compared with medical management, marking a new intervention for MVO–which accounts for almost 50% of ischemic stroke. 

PRIMARY ENDPOINT* 
Efficacy and safety composite 

The Positive Primary Endpoint Is In 

DISTALS and TIGERTRIEVER 13™ delivered 3x improvement in successful reperfusion without symptomatic intracranial hemorrhage (sICH) events. 

Designed for distals 

DISTALS pairs the first device and the trial specifically designed for the delicate anatomy of distal stroke. 

A distal-specific device​

TIGERTRIEVER 13 is purpose-built for small, tortuous vessels, with an adjustable design that optimizes clot engagement while minimizing vessel stress

A clinically meaningful endpoint

DISTALS uses CT perfusion (CTP) to measure brain tissue reperfusion, not just vessel opening. In distal stroke, vessel-based scores alone (such as TICI) may not reflect the extent of brain saved, making CTP a more informative endpoint. 

A distal-specific device​

Independent imaging core lab and strict oversight

Engineered for smaller vessels 

The only adjustable microtriever—TIGERTRIEVER™ 13 reduces retrieval force and vessel stress while preserving the radial force needed for effective clot integration. 

  • Ultra-low delivery profile, 1.3 Fr microcatheter-compatible 
  • Complete visibility and adjustability 
  • Adjustable in increments to tailor to patient anatomy

Additional resources 

Three-month clinical outcomes collection is ongoing as part of the DISTALS study protocol and will be reported in 2026. 


TIGERTRIEVER™ 13 is not indicated for LVO in all markets. Refer to the appropriate IFU for indications and contraindications. 



References: 

  1. Goyal M, Ospel JM, Ganesh A, et al. Endovascular Treatment of Stroke Due to Medium-Vessel Occlusion. N Engl J Med. 2025;392(14):1385-1395. doi:10.1056/NEJMoa2411668 
  2. Psychogios M, Brehm A, Ribo M, et al. Endovascular Treatment for Stroke Due to Occlusion of Medium or Distal Vessels. N Engl J Med. 2025;392(14):1374-1384. doi:10.1056/NEJMoa2408954 
  3. DISCOUNT Trial. Presented at the International Stroke Conference (ISC); February 2025; Los Angeles, CA.